NASDAQ:VOR • US9290332074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VOR BIOPHARMA INC (VOR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-19 | Wells Fargo | Initiate | Overweight |
| 2026-01-09 | Citigroup | Initiate | Buy |
| 2025-12-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-17 | TD Cowen | Initiate | Buy |
| 2025-12-09 | JP Morgan | Initiate | Overweight |
| 2025-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-15 | Baird | Upgrade | Neutral -> Outperform |
| 2025-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-30 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-06-27 | Baird | Maintains | Neutral -> Neutral |
| 2025-06-26 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-05-09 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-05-09 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-03-21 | Stifel | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-10 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | Baird | Maintains | Outperform -> Outperform |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-06 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-13 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 253.98% | N/A 129.30% | N/A 127.91% | N/A -1.02% | N/A 25.24% | ||||||||
| EBITDA YoY % growth | -2.84M | -10.33M -263.73% | -42.76M -313.94% | -67.59M -58.07% | -90.89M -34.47% | -122.544M -34.83% | -117.657M 3.99% | N/A -210.98% | N/A 55.58% | N/A -34.83% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.86M | -10.42M -264.34% | -43.37M -316.22% | -69.02M -59.14% | -93.42M -35.35% | -126.036M -34.91% | -121.185M 3.85% | N/A -205.08% | N/A 58.16% | N/A -44.78% | N/A 16.06% | N/A 18.40% | N/A 118.45% | N/A 1,784.82% | N/A 8.04% | N/A 56.05% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -43.00 85.44% | -46.80 -8.84% | -35.20 24.79% | -34.00 3.41% | N/A -278.79% | N/A 95.72% | N/A 1.78% | N/A -9.42% | N/A 67.15% | N/A 125.19% | N/A 625.77% | N/A 153.69% | N/A 28.84% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.66 81.18% | -1.01 80.66% | -1.15 97.38% | -1.23 63.02% | -1.40 15.25% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -29.651M -6.72% | -30.705M 5.42% | -40.947M 84.91% | -42.417M -68.03% | N/A |
| EBIT Q2Q % growth | -29.682M 5.20% | -31.068M 6.68% | -36.096M 86.84% | -38.465M -36.85% | -39.818M -34.15% |
All data in USD
11 analysts have analysed VOR and the average price target is 39.44 USD. This implies a price increase of 227.57% is expected in the next year compared to the current price of 12.04.
VOR BIOPHARMA INC (VOR) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of VOR BIOPHARMA INC (VOR) is -1.66 USD and the consensus revenue estimate is 0 USD.
The consensus rating for VOR BIOPHARMA INC (VOR) is 83.6364 / 100 . This indicates that analysts generally have a positive outlook on the stock.